Indivior Pharmaceuticals Inc. (INDV) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, INDV scores 51 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillar scores are: Fundamental Cash Engine 11/20 (ROIC 62.2%; FCF yield -2.24%); Whale/13F Flow 10/20 (institutional accumulation and options positioning); Insider Conviction 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 7/20 (Beta 1.15; sector sensitivity); and Forensic Balance Sheet 14/20 (Altman Z 3.13; Piotroski F 5/9; Debt/Equity 0.85).

The pillar mix shows the rating's central tension. Returns on invested capital are reported as very high at 62.2%, yet the free cash flow yield is negative at -2.24%, so the reported profitability is not translating into cash available to shareholders on the RQD's measure. The balance-sheet pillar is the strongest component, supported by an Altman Z of 3.13 and a Piotroski F of 5/9, while insider and institutional pillars are weak. The macro pillar is the lowest, reflecting a beta of 1.15, which the rating treats as above-market sensitivity. For a prospective investor, the practical reading is that the score argues against treating the stock's earnings multiple alone as a sufficient reason to buy, and that the valuation case depends on whether cash generation catches up with reported earnings. This is an analytical framing of the source data, not personalized advice.

Per the SEC financials, revenue rose from $1093.0M in FY 2023 to $1239.0M in FY 2025, and net income moved from $-126.0M to $210.0M over the same span. Per the market data, gross margin is 80.2%, operating margin 21.1%, and net margin 16.9%, with ROIC at 62.2%. The FY 2025 free cash flow of $-93.0M is consistent with the negative FCF yield of -2.24%. Per the Roarable RQD rating, the Altman Z-Score is 3.13 and the Piotroski F-Score is 5/9. The Debt/Equity ratio is 0.85, and reported debt declined from $535.5M in FY 2023 to $290.0M in FY 2025, while cash was $195.0M at the latest reported period.

Per the recent news feed, the catalysts and items are:

• A GREEN-tagged CATALYST item citing SUBLOCADE growth and improving profitability as creating upside potential (Seeking Alpha).
• A YELLOW-tagged MARKET WIRE item noting the stock up 4.4% alongside a GuruFocus valuation reference.
• A YELLOW-tagged MARKET WIRE item framing INDV as possibly 30% undervalued on its turnaround narrative (Yahoo Finance).
• A YELLOW-tagged MARKET WIRE item reporting shareholder approval of a proposed merger with Supernus (MarketScreener).
• Additional YELLOW-tagged market-wire items from Yahoo! Finance Canada and TradingView covering market action and estimates.

Per the Butterfly Supply-Chain Graph, the supply-chain designation is NONE, with no butterfly links and no proprietary signals. Risk watch items are the pending merger with Supernus, which the news feed reports shareholders have approved, and the negative FCF in the most recent period.

• What drives the gap between the 62.2% ROIC and the -2.24% FCF yield, and does FY 2025's -$93.0M free cash flow reflect working capital, capital expenditure, or one-time items?
• What are the terms, timing, and financial implications of the proposed Supernus merger, and how would they affect the balance sheet and share count?
• What share of revenue comes from SUBLOCADE versus other products, and how sustainable is the profitability growth the news feed describes?
• Who are the institutional and insider holders behind the whale and insider pillar scores, and what is the direction and size of recent activity?
• What is the analyst consensus and price-target range, given that no analyst data was provided?